Monopar Therapeutics Quarterly Operating Income (Loss) in USD from Q1 2017 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Monopar Therapeutics quarterly/annual Operating Income (Loss) history and growth rate from Q1 2017 to Q3 2024.
  • Monopar Therapeutics Operating Income (Loss) for the quarter ending September 30, 2024 was -$1.57M, a 23.8% increase year-over-year.
  • Monopar Therapeutics Operating Income (Loss) for the twelve months ending September 30, 2024 was -$7M, a 28.8% increase year-over-year.
  • Monopar Therapeutics annual Operating Income (Loss) for 2023 was -$8.83M, a 16.2% increase from 2022.
  • Monopar Therapeutics annual Operating Income (Loss) for 2022 was -$10.5M, a 15.4% decline from 2021.
  • Monopar Therapeutics annual Operating Income (Loss) for 2021 was -$9.13M, a 40.2% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$7M -$1.57M +$491K +23.8% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-08
Q2 2024 -$7.49M -$1.79M +$539K +23.2% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-09
Q1 2024 -$8.03M -$1.72M +$802K +31.7% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 -$8.83M -$1.91M +$997K +34.3% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-28
Q3 2023 -$9.83M -$2.07M +$341K +14.2% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-08
Q2 2023 -$10.2M -$2.33M +$435K +15.7% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-09
Q1 2023 -$10.6M -$2.53M -$67.9K -2.76% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 -$10.5M -$2.91M -$228K -8.5% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-28
Q3 2022 -$10.3M -$2.41M +$51.7K +2.1% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$10.4M -$2.76M -$671K -32.1% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 -$9.69M -$2.46M -$562K -29.7% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 -$9.13M -$2.68M -$420K -18.6% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-23
Q3 2021 -$8.71M -$2.46M -$811K -49.2% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$7.9M -$2.09M -$628K -42.9% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 -$7.27M -$1.89M -$759K -66.8% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 -$6.51M -$2.26M -$1.04M -84.6% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-24
Q3 2020 -$5.47M -$1.65M -$889K -117% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 -$4.58M -$1.46M -$532K -57.1% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 -$4.05M -$1.14M +$271K +19.3% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
Q4 2019 -$4.32M -$1.22M -$126K -11.5% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-25
Q3 2019 -$4.2M -$759K -$91.9K -13.8% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 -$4.11M -$932K -$265K -39.6% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 -$3.84M -$1.41M -$510K -56.8% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 -$3.33M -$1.1M -$362K -49.1% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-27
Q3 2018 -$2.97M -$668K +$14.2M +95.5% Jul 1, 2018 Sep 30, 2018 10-Q 2018-11-09
Q2 2018 -$17.2M -$668K -$72.6K -12.2% Apr 1, 2018 Jun 30, 2018 10-Q 2019-11-12
Q1 2018 -$17.1M -$897K -$523K -140% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-10
Q4 2017 -$16.6M -$737K Oct 1, 2017 Dec 31, 2017 10-K 2019-02-26
Q3 2017 -$14.9M Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-09
Q2 2017 -$595K Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-09
Q1 2017 -$374K Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.